Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 6/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601650 | 0.87 | DHODH (0.47) | ACMSDMYCNPC1RAB9ANOTUM | |
| SCHEMBL13601631 | 0.85 | LDHA (0.49) | ACMSDMYCNOTUMDHODHMCL1 | |
| SCHEMBL13601588 | 0.83 | AKR1C3 (0.50) | MYCNOTUMDHODHALDH1A1 | |
| SCHEMBL13601657 | 0.82 | MYC (0.42) | ACMSDMYCNOTUMDHODHALB | |
| SCHEMBL15630645 | 0.80 | DHODH (0.50) | ACMSDMYCNPC1RAB9ANOTUM | |
| SCHEMBL13601645 | 0.80 | FABP4 (0.52) | MYCDHODHALDH1A1 | |
| SCHEMBL269331 | 0.80 | NPC1 (0.60) | ACMSDMYCNPC1RAB9AGPR35 | |
| SCHEMBL13601629 | 0.78 | DHODH (0.49) | DHODHALDH1A1KDM4ELDHA | |
| SCHEMBL13601658 | 0.78 | TAS2R14 (0.42) | MYCNOTUMDHODH | |
| SCHEMBL2429144 | 0.78 | LDHA (0.49) | ACMSDMYCNOTUMDHODHMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | ACMSD 3604/4885MYC 3353/4885NPC1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.